Pharmaceutical leader Eli Lilly has announced a major expansion into the infectious disease sector, committing approximately $4 billion to acquire three specialized biotechnology firms. The strategic move involves the integration of Curevo, LimmaTech Biologics, and the Vaccine Company, a trio of acquisitions designed to bolster the company’s research and development infrastructure in vaccine technology and […]